Cadila Pharmaceuticals Ltd vs DCIT: Detailed Analysis of ITAT Ahmedabad Ruling

The Ahmedabad bench of the Income Tax Appellate Tribunal (ITAT) in the case of Cadila Pharmaceuticals Ltd vs DCIT dealt with a wide spectrum of income tax issues arising in Assessment Years 2013-14 and 2014-15. The Tribunal was called upon to examine transfer pricing adjustments, allowability of interest, weighted deduction for R&D, treatment of product registration expenses, disallowance under Section 14A and its impact on Section 115JB, treatment of foreign exchange derivative losses, disallowance of medical freebies, delayed employee welfare fund contributions, and a claim under Section 43B for bonus.

The order is a judicial decision (full text), so what follows is a structured summary of the key findings and principles emerging from the judgment, organised issue-wise for ease of reference.

1. Corporate Guarantee as an “International Transaction” under Section 92B

Facts

  • The assessee, Cadila Pharmaceuticals Limited, had extended a corporate guarantee to Allahabad Bank in favour of its overseas Associated Enterprise (AE), Satellite Overseas Holdings Ltd., UK.
  • No fresh guarantee was issued during the relevant year; it was a continuation of guarantees given in earlier years.
  • No fee, commission, margin money, or other consideration was charged or paid.
  • The Transfer Pricing Officer (TPO) treated the corporate guarantee as an “international transaction” under Section 92B and computed an arm’s length commission at 1.24%, making an upward adjustment of Rs. 74,02,428/-.
  • The assessee argued that the guarantee was a shareholder support activity, not involving any cost, economic sacrifice, or impact on its profit, income or assets, and therefore outside the ambit of Section 92B.

Tribunal’s Key Reasoning

  • For earlier years (A.Ys. 2010-11 and 2011-12), the same assessee had faced an identical adjustment on corporate guarantee, which the Coordinate Bench had already deleted.
  • The Tribunal earlier held that a cost-free corporate guarantee, issued for group support without any economic burden on the guarantor, does not fit within the scope of “international transaction” as envisaged in Section 92B, since there is no bearing on profits, income, losses or assets.
  • In the present year:
    • The CIT(A) recorded that no new corporate guarantee was issued in the relevant year.
    • The assessee did not incur any cost, margin, collateral, or financial exposure requiring compensation from the AE.
  • The Revenue could not demonstrate any distinguishing facts or legal basis vis-à-vis the earlier years.

Decision

  • Following its own earlier orders in Cadila’s case and maintaining judicial consistency, the Tribunal upheld the CIT(A)’s deletion of the transfer pricing adjustment of Rs. 74,02,428/-.
  • Grounds of appeal raised by the Revenue on this issue were dismissed.

Note: The Tribunal emphasised that, under the then-prevailing interpretation, a mere supporting corporate guarantee without cost or economic impact is not per se an “international transaction” warranting benchmarking, unless it demonstrably affects the guarantor’s profits or assets.

2. Disallowance of Interest under Section 36(1)(iii)

Facts

  • The Assessing Officer (AO) disallowed Rs. 63,27,480/- under Section 36(1)(iii) alleging that the assessee:
    • had borrowed funds on which interest was paid, and
    • simultaneously gave interest-free advances to group entities such as Casil Health Products Ltd., Casil Industries Ltd., Karnavati Engineering Ltd., Omnicare Pharmaceuticals Ltd., and IRM Enterprises Pvt. Ltd.
  • AO’s premise: borrowed funds were diverted for non-business purposes; hence, proportionate interest should be disallowed.
  • The assessee contended:
    • Advances were driven by commercial expediency and were integrally linked with its business (job work, purchases, strategic support, operational facilitation, etc.).
    • It had substantial own funds and reserves, creating a presumption that interest-free advances were out of non-interest-bearing funds.
    • In earlier years, similar disallowances had already been deleted by the ITAT and upheld by the Gujarat High Court.

Tribunal’s Key Reasoning

  • The CIT(A) concluded that:
    • The AO failed to show direct nexus between specific borrowed funds and the interest-free advances.
    • The advances were business-oriented and made for commercial reasons.
  • Tribunal relied on binding precedents:
    • S.A. Builders Ltd. vs CIT (2007) 288 ITR 1 (SC): if there is nexus between the expenditure and business purpose, Revenue cannot sit in judgment over business decisions.
    • CIT vs Raghuvir Synthetics Ltd. (2013) 354 ITR 222 (Guj): where both interest-free funds and interest-bearing funds exist, presumption favours use of interest-free funds for non-interest-bearing advances.
  • In Cadila’s own earlier years (A.Ys. 2006-07, 2007-08, 2011-12), similar disallowances were consistently deleted, and those orders were affirmed by the jurisdictional High Court.

Decision

  • The Tribunal agreed with the CIT(A) that:
    • Commercial expediency was established, and
    • No direct linkage of borrowed funds to advances was proved.
  • Disallowance under Section 36(1)(iii) of Rs. 63,27,480/- was deleted, and Revenue’s ground was rejected.

3. Weighted Deduction under Section 35(2AB) – DSIR Form 3CL vs Actual Expenditure

Facts

  • The assessee operated an approved in-house R&D facility and claimed weighted deduction under Section 35(2AB).
  • AO restricted the deduction to amounts quantified in Form 3CL by DSIR, and **disallowed Rs.